Fisher Andrew 4/A
4/A · Verona Pharma plc · Filed Jun 18, 2025
Insider Transaction Report
Form 4/AAmended
Fisher Andrew
General Counsel
Transactions
- Exercise/Conversion
Ordinary Shares
2025-05-15$2.01/sh+80,000$160,904→ 439,999 total - Exercise/Conversion
Share Options (Right to Buy)
2025-05-15−80,000→ 2,320,000 totalExercise: $2.01Exp: 2034-03-31→ Ordinary Shares (80,000 underlying)
Footnotes (4)
- [F1]This amendment is being filed to correct the Reporting Person's Form 4 filed on May 16, 2025, which contained a typographical error in the price reported.
- [F2]Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
- [F3]The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer.
- [F4]The option vested and became exercisable as to 25% on March 4, 2025. The remainder of the shares vested or will vest in 36 equal monthly installments thereafter.